Imugene Ltd has released a press release.
Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene Share Placement raises $3.2 million
- Imugene receives $1.3m R&D Tax Refund
- Imugene successfully completes preclinical animal studies
- Imugene Final Cancer Vaccine Doses Delivered to GMP Depot
- Imugene Receives Approval to Start Gastric Cancer Study
Later from Imugene
- Leslie Chong Appointed Chief Executive Officer
- Acquisition of immuno-oncology technology
- Response to ASX Aware Query
- Imugene progresses mimotope platform
- BMC Cancer journal publishes encouraging HER-Vaxx research
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene